In vivo receptor occupancy and plasma concentration of pranidipine, a potent and long-acting dihydropyridine calcium antagonist

Pharmacology

Volumn 59, Issue 4, 1999, Pages 171-182

  Yamada, Shizuo ^a   Uchida, Shinya ^b   Urayama, Akihiko ^b   Kimura, Ryohei ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NONE

Author keywords

Aorta; Brain; DHP receptors; Myocardium; Pranidipine; Receptor occupancy in vivo

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; CALCIUM ANTAGONIST; ISRADIPINE; NIFEDIPINE; PRANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BINDING SITE; BRAIN CORTEX; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HEART MUSCLE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

EID: 0032826165     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028318     Document Type: Article

References (26)

1. 3H]Nitrendipine, a potent calcium antagonist. Arzneimittelforsch/Drug Res 1981;31: 2064-2067.
2. Bolger CT, Gengo PT, Luckowski EM, Siegel H, Triggle DJ, Janis RA: High affinity binding of calcium channel antagonists to smooth and cardiac muscle. Biochem Biophys Res Commun 1982;104:1604-1609.
3. 3H]-nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex and ileum of rats. Life Sci 1982;30:2191-2202.
4. 3H]Nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Natl Acad Sci USA 1982; 79:36356-36360.
5. 3H]PN 200-110 in coronary artery. J Pharmacol Exp Ther 1990;252:327-332.
6. Kelly JG, O'Malley K: Clinical pharmacokinetics of calcium antagonists: Clin Pharmacokinet 1992; 23:1-10.
7. Meredith PA, Elliott HL: Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992;22:22-31.
8. Nakayama N, Ikezono K, Mori T, Yamashita S, Nakayama S, Tanaka Y, Hosokawa T, Minami Y, Masutani K, Yamamura Y, Yabuuchi Y: Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats. J Cardiovasc Pharmacol 1990;15:836-844.
9. Miyakoda G, Nakayama N, Matsui K, Yabuuchi Y: Mechanisms of the potent and long-lasting antihypertensive action of the new calcium channel blocker pranidipine: Evidence for strong affinity to the calcium channels or membranes. Arzneimittelforsch/Drug Res 1995; 45(I):471-475.
10. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:721-732.
11. 3H]PN 200-110 binding to dihydro-pyridine receptors associated with channels in rat cerebral cortex and heart. Life Sci 1984;35:721-732.
12. Yamada S, Matsuoka Y, Kato Y, Kimura R, Inagaki O: A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensvie rats. J Pharmacol Exp Ther 1992;262:589-594.
13. 2+ channel antagonist, in spontaneously hypertensive rats. Eur J Pharmacol 1995;287:191-196.
14. Uchida S, Yamada S, Ohkura T, Heshikiri M, Yoshimi A, Shirahase H, Kimura R: The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats. Br J Pharmacol 1995;114:217-223.
15. 3H]WB4101: Effect of 6-hydroxydopamine treatment. J Pharmacol Exp Ther 1980;215:176-185.
16. Rosenthal HE: Graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 1967;20: 525-532.
17. Yamada S, Sugimoto N, Uchida S, Deguchi Y, Kimura R: Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J Cardiovasc Pharmacol 1994; 23:466-472.
18. Yamada S, Kimura R: Pharmacodynamics and pharmacokinetics of iganidipine. Cardiovasc Drug Rev 1996;14:213-230.
19. Yamada S, Uchida S, Ohkura T, Sugimoto N, Deguchi Y, Kimura R: Pharmacokinetics of a third-generation dihydropyridine calcium antagonist, amlodipine and its occupation of cardiovascular receptors (in Japanese). Jpn Pharmacol Ther 1995;23: 75-86.
20. 3H]-nitrendipine. Eur J Pharmacol 1983;88:275-276.
21. 3H]PN 200-110 with calcium channel binding sites in rat brain. J Neural Transm 1984;60:149-167.
22. 3H]nimodipine in rat brain after transient forebrain ischemia. J Cereb Blood Flow Metab 1994;14:397-405.
23. Takata Y, Kato H: Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine and nicardipine administered orally to conscious renal hypertensive dogs. Arzneimittelforsch/Drug Res 1986; 36:1464-1471.
24. Graefe KH, Ziegler R, Wingender R, Ramsch KD, Schmitz H: Plasma concentration-response relationships for some cardiovascular effects of dihydropyridines in healthy subjects. Clin Pharmacol Ther 1988;43: 16-22.
25. Wu WH, Henderson BM, Lanc R, Garnes D, Yacobi A, Silber BM: Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. Drug Metab Dispos 1988;16:222-227.
26. Yamanaka K, Suzuki M, Muneyasu S, Ishiko J: Antihypertensive effects of amlodipine, a new calcium antagonist (in Japanese). Folia Pharmacol Jpn 1991;97:115-126.